Valion Bio, Inc.
No SEC Form 4 filings for $VBIO in the last 30 days.
See all $VBIO insider activity →Valion Bio, Inc. (Nasdaq:VBIO) announced a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement. The split, approved by shareholders, will take effect on August 31, 2026, and trading will resume under the same symbol. The company aims to regain compliance and maintain its Nasdaq listing.
Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 1.01 Entry into a Material Definitive Agreement The Company and 3i, LP (“3i”) are parties to that certain Securities Purchase Agreement, dated April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the pu
Valion Bio (Nasdaq:VBIO) said Ukraine’s Ministry of Health accepted its Entolimod dossier for formal review on July 22, 2026, and started a technical assessment with questions on physicochemical characterization for a potential stockpiling supply. The company expects a possible decision as early as Q4 2026, which could enable national registration and potential future government procurement, though no deal is signed.
Over the past 7 days, alphai's AI scored 1 news story mentioning VBIO (Valion Bio, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent VBIO coverage spans corporate actions, regulation and financial news.
The reverse split will reduce share count and increase price per share, potentially improving liquidity and meeting listing requirements.
The filing signals governance/officer updates plus a royalty and guarantee arrangement that could affect cash flows and counterparty risk.
A defined regulatory milestone increases the probability of Entolimod’s first national registration, but revenue impact is still indirect until procurement is agreed.
Near-term catalyst is the start of the safety study, with a larger binary-style read-through in early fall from the therapeutic study.
The 8-K discloses milestone-linked financing/consideration mechanics that can affect dilution expectations and near-term funding runway.
alphai scores every news story that mentions VBIO with an AI model for sentiment and relevance, and aggregates insider trades from Valion Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Valion Bio, Inc. (Nasdaq:VBIO) announced a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement. The split, approved by shareholders, will take effect on August 31, 2026, and trading will resume under the same symbol. The company aims to regain compliance and maintain its Nasdaq listing.
2 min readValion Bio, Inc. (VBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 1.01 Entry into a Material Definitive Agreement The Company and 3i, LP (“3i”) are parties to that certain Securities Purchase Agreement, dated April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the pu
3 min readValion Bio (Nasdaq:VBIO) said Ukraine’s Ministry of Health accepted its Entolimod dossier for formal review on July 22, 2026, and started a technical assessment with questions on physicochemical characterization for a potential stockpiling supply. The company expects a possible decision as early as Q4 2026, which could enable national registration and potential future government procurement, though no deal is signed.
6 min readValion Bio (Nasdaq:VBIO) said AFRRI, under a contract with NIAID, is running U.S. government-funded studies of Entolimod for radiation-induced GI injury. A safety study is planned to start this week, followed by a therapeutic study with top-line data expected in early fall. The program aims to assess survival and GI recovery after lethal radiation doses.
4 min readValion Bio, Inc. (VBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On July 31, 2026, the Company issued an aggregate of 1,287.8685 shares of Series A Preferred Stock (“Milestone Shares”), as consideration for the Milestone Payment (as discussed in more detail in
4 min readValion Bio, Inc. (VBIO) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Tivic Health Systems, Inc. Form 8-K false 0001787740 0001787740 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securitie
3 min read